Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Golimumab.

Literature DB >> 20065639

Golimumab.

Abstract

Golimumab, a human anti-TNFalpha IgG1kappa monoclonal antibody, was approved in the US and Canada in April 2009 as a treatment for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, and is undergoing regulatory review in the EU for these indications. The product was developed by Centocor and Janssen Pharmaceutical KK (Johnson & Johnson subsidiaries), in collaboration with Schering-Plough and Mitsubishi Tanabe Pharma. Golimumab faces numerous protein therapeutic competitors on the market, but, as the first patient-administered, once-monthly dosed anti-TNFalpha drug, it will likely be an attractive option for patients.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2009 PMID： 20065639 PMCID： PMC2759491 DOI： 10.4161/mabs.1.5.9286

Source DB: PubMed Journal: MAbs ISSN： 1942-0862 Impact factor: 5.857

14 in total

1. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.

Authors: Stanley B Cohen; Paul Emery; Maria W Greenwald; Maxime Dougados; Richard A Furie; Mark C Genovese; Edward C Keystone; James E Loveless; Gerd-Rüdiger Burmester; Matthew W Cravets; Eva W Hessey; Timothy Shaw; Mark C Totoritis
Journal: Arthritis Rheum Date: 2006-09

2. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.

Authors: Honghui Zhou; Haishan Jang; Roy M Fleischmann; Esther Bouman-Thio; Zhenhua Xu; Joseph C Marini; Charles Pendley; Qun Jiao; Gopi Shankar; Stanley J Marciniak; Stanley B Cohen; Mahboob U Rahman; Daniel Baker; Mary Ann Mascelli; Hugh M Davis; Daniel E Everitt
Journal: J Clin Pharmacol Date: 2007-03 Impact factor: 3.126

3. Reviews Preclinical Safety and Immune-Modulating Effects of Therapeutic Monoclonal Antibodies to Interleukin-6 and Tumor Necrosis Factor-alpha in Cynomolgus Macaques.

Authors: Pauline L Martin; Joel Cornacoff; Uma Prabhakar; Thomas Lohr; George Treacy; Jessica E Sutherland; Sarah Hersey; Elise Martin
Journal: J Immunotoxicol Date: 2005-07-01 Impact factor: 3.000

4. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I.

Authors: Charles G Helmick; David T Felson; Reva C Lawrence; Sherine Gabriel; Rosemarie Hirsch; C Kent Kwoh; Matthew H Liang; Hilal Maradit Kremers; Maureen D Mayes; Peter A Merkel; Stanley R Pillemer; John D Reveille; John H Stone
Journal: Arthritis Rheum Date: 2008-01

5. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma.

Authors: Sally E Wenzel; Peter J Barnes; Eugene R Bleecker; Jean Bousquet; William Busse; Sven-Erik Dahlén; Stephen T Holgate; Deborah A Meyers; Klaus F Rabe; Adam Antczak; James Baker; Ildiko Horvath; Zsuzsanna Mark; David Bernstein; Edward Kerwin; Rozsa Schlenker-Herceg; Kim Hung Lo; Rosemary Watt; Elliot S Barnathan; Pascal Chanez
Journal: Am J Respir Crit Care Med Date: 2009-01-08 Impact factor: 21.405

6. E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy.

Authors: Sudha Visvanathan; Carrie Wagner; Jeannie Rojas; Jonathan Kay; Bhaskar Dasgupta; Eric L Matteson; Michael Mack; Daniel G Baker; Mahboob U Rahman
Journal: J Rheumatol Date: 2009-06-01 Impact factor: 4.666

7. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.

Authors: Robert D Inman; John C Davis; Désirée van der Heijde; Laura Diekman; Joachim Sieper; Sung Il Kim; Michael Mack; John Han; Sudha Visvanathan; Zhenhua Xu; Benjamin Hsu; Anna Beutler; Jürgen Braun
Journal: Arthritis Rheum Date: 2008-11

Review 8. Tocilizumab: a review of its use in the management of rheumatoid arthritis.

Authors: Vicki Oldfield; Sohita Dhillon; Greg L Plosker
Journal: Drugs Date: 2009 Impact factor: 9.546

9. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.

Authors: Arthur Kavanaugh; Iain McInnes; Philip Mease; Gerald G Krueger; Dafna Gladman; Juan Gomez-Reino; Kim Papp; Julie Zrubek; Surekha Mudivarthy; Michael Mack; Sudha Visvanathan; Anna Beutler
Journal: Arthritis Rheum Date: 2009-04

10. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.

Authors: E C Keystone; M C Genovese; L Klareskog; E C Hsia; S T Hall; P C Miranda; J Pazdur; S-C Bae; W Palmer; J Zrubek; M Wiekowski; S Visvanathan; Z Wu; M U Rahman
Journal: Ann Rheum Dis Date: 2008-12-09 Impact factor: 19.103

20 in total

Review 1. Development trends for human monoclonal antibody therapeutics.

Authors: Aaron L Nelson; Eugen Dhimolea; Janice M Reichert
Journal: Nat Rev Drug Discov Date: 2010-09-03 Impact factor: 84.694

Review 2. Mining human antibody repertoires.

Authors: Roger R Beerli; Christoph Rader
Journal: MAbs Date: 2010-07-01 Impact factor: 5.857

3. A new CHO (Chinese hamster ovary)-derived cell line expressing anti-TNFα monoclonal antibody with biosimilar potential.

Authors: Mateus Dalcin Luchese; Mariana Lopes Dos Santos; Angelica Garbuio; Roselaine Campos Targino; Carla Ploeger Mansueli; Lilian Rumi Tsuruta; Wagner Quintilio; Ana Maria Moro
Journal: Immunol Res Date: 2018-06 Impact factor: 2.829

4. 6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland.

Authors: Alain Beck; Thierry Wurch; Janice M Reichert
Journal: MAbs Date: 2011-03-01 Impact factor: 5.857

5. Two cases of Erythrodermic psoriasis treated with Golimumab.

Authors: Mayssoun Kudsi; Mhd Amin Alzabibi; Mosa Shibani
Journal: Ann Med Surg (Lond) Date: 2022-06-08

Review 6. Treatment of Crohn's disease in pregnant women: drug and multidisciplinary approaches.

Authors: Didia Bismara Cury; Alan C Moss
Journal: World J Gastroenterol Date: 2014-07-21 Impact factor: 5.742

7. Identification, Efficacy, and Stability Evaluation of Succinimide Modification With a High Abundance in the Framework Region of Golimumab.

Authors: Tao Liu; Jin Xu; Qingcheng Guo; Dapeng Zhang; Jun Li; Weizhu Qian; Huaizu Guo; Xinli Zhou; Sheng Hou
Journal: Front Chem Date: 2022-04-05 Impact factor: 5.545